Bicara Therapeutics is a clinical-stage biopharmaceutical company with no approved products or revenue, entirely focused on developing its single lead candidate, ficerafusp alfa, for the treatment of solid tumors. Ficerafusp alfa is a bifunctional antibody that simultaneously targets EGFR (a protein overexpressed on many tumor cells) and neutralizes TGF-β, a signaling molecule that shields tumors from immune attack and drives resistance to existing therapies. By combining these two mechanisms in one molecule, ficerafusp alfa is designed to localize its effect within the tumor microenvironment rather than acting systemically. The primary target indication is first-line recurrent/metastatic HPV-negative head and neck squamous cell carcinoma (HNSCC), where the current standard-of-care pembrolizumab achieves only around a 19% overall response rate. Bicara is developing ficerafusp alfa in combination with pembrolizumab, and Phase 1b data showed a 54% overall response rate and median overall survival of 21.3 months in this population. The pivotal FORTIFI-HN01 Phase 2/3 trial began enrolling patients in early 2025, with an interim analysis targeted for mid-2027 that could support an accelerated FDA approval filing. Beyond HNSCC, Bicara is also exploring ficerafusp alfa in colorectal cancer, cutaneous squamous cell carcinoma, and anal squamous cell carcinoma. Bicara licensed ficerafusp alfa from Biocon under a clean structure with no ongoing milestones or royalties, and relies on third-party contract manufacturers for clinical and potential commercial supply.